News Releases

All Years

Search

Go

Advanced Search

MAY 13, 2021
Inhibrx Reports First Quarter 2021 Financial Results

MAR 12, 2021
Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021
Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021
Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist